secwatch.observer — SEC 8-K summary
======================================

Issuer:     PUMA BIOTECHNOLOGY, INC. (PBYI)
CIK:        0001401667
Form:       8-K
Filed at:   2023-09-26T23:59:59+00:00
Accession:  0001437749-23-026766
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Puma announces acceptance of alisertib + pembrolizumab poster at AACR-NCI-EORTC conference
--------------------------------------------------------------------------------

- Investigator-sponsored Phase I/II trial of alisertib plus pembrolizumab accepted for poster presentation.
- Trial targets Rb-deficient head and neck squamous cell carcinoma (HNSCC).
- Poster presentation at late-breaking session C on Oct 14, 2023, 12:30-4:00 pm ET, as LB_C12.
- Conference: 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
- No clinical data results announced; this is a trial update.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923026766/0001437749-23-026766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401667/000143774923026766/pbyi20230925_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-026766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer